Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from MediPharm Labs ( (TSE:LABS) ) is now available.
MediPharm Labs announced a leadership transition, with Chief Executive Officer David Pidduck stepping down effective January 23, 2026, while remaining on the board, and Chief Financial Officer Greg Hunter taking on the role of interim CEO while retaining his CFO responsibilities. The board highlighted Pidduck’s role in restructuring the business, improving profitability and integrating the VIVO Cannabis acquisition, and emphasized Hunter’s track record in cost reduction, financial and operational controls, and commercial strategy, noting that his broad experience at major global healthcare companies positions him to maintain operational discipline and support the company’s growth and competitive positioning during the transition period.
The most recent analyst rating on (TSE:LABS) stock is a Hold with a C$0.07 price target. To see the full list of analyst forecasts on MediPharm Labs stock, see the TSE:LABS Stock Forecast page.
Spark’s Take on TSE:LABS Stock
According to Spark, TipRanks’ AI Analyst, TSE:LABS is a Neutral.
The overall stock score is primarily influenced by financial performance challenges, including negative profitability and cash flow issues. Technical analysis indicates a bearish trend, and valuation metrics reflect ongoing losses, resulting in a lower score.
To see Spark’s full report on TSE:LABS stock, click here.
More about MediPharm Labs
MediPharm Labs is a pharmaceutical company focused on precision-based cannabinoids, specializing in the development and manufacture of purified, pharmaceutical‑quality cannabis concentrates, active pharmaceutical ingredients and advanced derivative products. Founded in 2015, it operates GMP‑certified, ISO‑standard facilities and has built a research-driven platform serving domestic and international medical cannabis markets, bolstered by a unique Health Canada Pharmaceutical Drug Establishment License and the 2023 acquisition of VIVO Cannabis Inc., which expanded its Canadian and overseas patient reach.
YTD Price Performance: 15.38%
Average Trading Volume: 352,939
Technical Sentiment Signal: Buy
Current Market Cap: C$31.56M
Find detailed analytics on LABS stock on TipRanks’ Stock Analysis page.